Perfusion MRI for Kidney Cancer

Overseen By Clinical Trials Office

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Rutgers, The State University of New Jersey

Disqualifiers: Severe disease, Renal impairment, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

75 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial team or your doctor.

Is perfusion MRI safe for humans?

The studies primarily focus on the effectiveness of perfusion MRI and related treatments in animal models, such as mice and rats, rather than directly addressing safety in humans. However, these imaging techniques are commonly used in clinical settings, suggesting a general acceptance of their safety for diagnostic purposes. ^{1 2 3 4 5}

How is perfusion MRI used in kidney cancer treatment different from other treatments?

Perfusion MRI for kidney cancer is unique because it uses advanced imaging techniques like arterial spin labeling (ASL) and dynamic contrast-enhanced (DCE) MRI to measure blood flow in tumors, helping to assess the effectiveness of antiangiogenic treatments. Unlike traditional treatments, this approach provides a non-invasive way to monitor how well a treatment is working by observing changes in tumor blood supply. ^{2 3 6 7 8}

What data supports the effectiveness of the treatment Arterial Spin Labeling Magnetic Resonance Imaging for kidney cancer?

Research shows that Arterial Spin Labeling (ASL) MRI can help identify how well kidney cancer responds to certain treatments by measuring changes in blood flow within tumors. This technique has been used to detect early responses to anti-cancer drugs in studies, suggesting it may be useful in monitoring treatment effectiveness. ^{2 3 5 9 10}

Who Is on the Research Team?

David Foran, PhD

Principal Investigator

Rutgers Cancer Institute of New Jersey

Are You a Good Fit for This Trial?

This trial is for adults with kidney tumors at least 1 cm in size, which can be non-metastatic or metastatic. Participants must understand and sign a consent form. Women of childbearing age need a negative pregnancy test. Those with severe diseases, poor kidney function (eGFR < 45), pregnant or breastfeeding women, and individuals unable to undergo MRI due to claustrophobia or metal implants are excluded.

Inclusion Criteria

Patients must be able to read, understand, and voluntarily sign an informed consent document

My kidney tumor is at least 1 cm big and hasn't spread, based on scans.

I have kidney cancer that has spread, but not to my lungs.

Exclusion Criteria

You have a known allergy to the contrast agent used for intravenous imaging.

I am not pregnant or breastfeeding.

Severe concurrent disease, infection, or medical co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Diagnostic Imaging

Participants undergo dynamic contrast enhanced (DCE), dynamic susceptibility contrast (DSC), or arterial spin labeled (ASL) perfusion MRI within 30 days of biopsy or surgery

4 weeks

1 visit (in-person)

Follow-up Imaging

Participants with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI

1-6 months

1-2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

48 hours

1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Arterial Spin Labeling Magnetic Resonance Imaging
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging
• Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
• Perfusion Magnetic Resonance Imaging

Trial Overview The study tests perfusion magnetic resonance imaging (MRI) techniques like Dynamic Susceptibility Contrast-Enhanced MRI and Arterial Spin Labeling MRI to diagnose kidney tumors and monitor treatment response. It's designed for patients who may have localized or spread cancer.

How Is the Trial Designed?

Group I: Diagnostic (pMRI) Experimental Treatment 4 Interventions

Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.

Who Is Running the Clinical Trial?

Rutgers, The State University of New Jersey

Lead Sponsor

Trials

471

Recruited

81,700+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Rutgers Cancer Institute of New Jersey

Collaborator

Trials

72

Recruited

22,200+

Citations

1. United States pubmed.ncbi.nlm.nih.gov

Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). [2012]

2. Germany pubmed.ncbi.nlm.nih.gov

Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. [2022]

6. England pubmed.ncbi.nlm.nih.gov

Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging. [2022]

7. England pubmed.ncbi.nlm.nih.gov

Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. [2021]

8. Greece pubmed.ncbi.nlm.nih.gov

Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma. [2013]

9. United States pubmed.ncbi.nlm.nih.gov

Renal perfusion imaging by MRI. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. [2022]